KRN-633 is primarily investigated for its anti-angiogenic and anti-tumor properties. It functions as a potent inhibitor of vascular endothelial growth factor receptor (VEGFR) tyrosine kinases, particularly targeting VEGFR-2, which plays a key role in tumor blood vessel formation. By blocking this pathway, KRN-633 suppresses the development of new blood vessels that supply nutrients to tumors, thereby inhibiting tumor growth and metastasis. It has shown promising activity in preclinical models of various solid tumors, including lung, ovarian, and colon cancers. Due to its ability to target tumor vasculature, it is being explored for use in combination with chemotherapy or other targeted therapies to enhance efficacy. Additionally, KRN-633 has demonstrated potential in reducing ascites accumulation in certain cancer models, suggesting possible application in managing malignant effusions. Research is ongoing to evaluate its pharmacokinetic profile and therapeutic window in vivo, with a focus on optimizing dosing strategies for potential clinical translation.